- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Healthcare leads markets after Senate bill's release.
Growth is crushing value, says Jim Cramer, and the dynamic is more pronounced in individual sectors.
Novartis released data from its RTH258 clinical trials illustrating that RTH258 does not need to be injected as often as Regeneron's rival drug, Eylea.